ERES East Resources Acquisition Company

Japan-Based International Drug Developer Awards $2 Million Thorough QT Study to eResearchTechnology Agreement Marks Another Significant Contract With a Japanese Drug Developer Demonstrating Continued Momentum of ICH, E14 Global Adoption PHILADELPHIA, June 27 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (NASDAQ:ERES), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it has been awarded a Thorough QT (T-QT) Study valued at more than $2 million in cardiac safety monitoring and services from the U.S. subsidiary of a leading Japan-based drug developer for one of its compounds in clinical trials. The contract follows an agreement with another Japan-based sponsor for a $1.6 million T-QT Study eRT announced last week, signaling momentum for global adoption of the recently finalized International Conference on Harmonisation (ICH), E14 cardiac safety guidance. eRT is providing comprehensive support, including provision of digital 12-lead ECG equipment designed to facilitate collection of cardiac safety data that is subsequently provided to eRT for analysis. eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT(R) workflow enabled data handling technology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards. "eRT is uniquely qualified to provide this sponsor with a turnkey solution to ensure compliance with the recently ratified ICH, E14 guidance for cardiac safety in new drug development," said Scott Grisanti, senior vice president of business development and chief marketing officer at eRT. "In addition to Best Practice cardiac safety services, eRT also facilitated expert scientific consulting on study design, leveraged its Certified Clinical Pharmacology Unit Partner Program, and included a partner specializing in bio-statistics services focused on T-QT Study requirements. eRT's ability to assemble a best of breed team comprised of individuals and organizations who have worked together closely across many T-QT studies delivered a compelling value proposition for this customer." Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. The sponsor may cancel this agreement at its sole discretion. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT: Joan Sterlacci of eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden of Hayden Communications, +1-858-704-5065, for eResearchTechnology, Inc. Web site: http://www.ert.com/

Copyright